Hepatitis C prevalence among HIV-positive MSM in San Francisco: 2004 and 2008.
Hepatitis C prevalence among HIV-positive MSM in San Francisco: 2004 and 2008.
复制标题
旧金山 HIV 阳性 MSM 中丙型肝炎患病率：2004 年和 2008 年。
DOI：
10.1097/olq.0b013e3181f68ed4
复制
发表时间：
2011
影响因子：
3.1
通讯作者：
McFarland,Willi
中科院分区：
文献类型：
--
作者：
Raymond,HFisher;Hughes,Alison;O'Keefe,Kara;Stall,RonD;McFarland,Willi
Recent reports suggest the potential for an epidemic of Hepatitis C among nonintravenous drug-using HIV-positive men who have sex with men. HIV-positive specimens from surveillance surveys in 2004 and 2008 were tested for HCV antibodies. Among noninjection drug using men who have sex with men, HCV prevalence was 8.7% and 4.5% in 2004 and 2008, respectively. There was no evidence of a change in HCV prevalence between 2004 and 2008.Reports from Europe and New York City have suggested a growing Hepatitus C Virus (HCV) epidemic among HIV-positive men who have sex with men (MSM). 1, 2 Furthermore, data indicate that sexual transmission may be the mechanism of HCV acquisition among noninjection drug using (IDU) MSM, 3, 4 in which case serosorting (ie, unprotected anal sex between HIV-positive partners) may fuel HCV transmission. 5 However, other studies from Seattle, San Diego, and New York City find low prevalence of HCV among non-IDU MSM. 6 A sexually-driven epidemic of HCV among HIV-positive MSM could have significant impact on the health of HIV-positive MSM. We, therefore, assessed HCV prevalence and changes in HCV prevalence among HIV-positive MSM through serological testing of specimens collected during surveys conducted in 2004 and 2008. As part of the US National HIV Behavioral Surveillance (NHBS) system, cross-sectional surveys of MSM were conducted in San Francisco in 2004 and in 2008, using a standardized time-location sampling protocol. 7 Serum samples from those participants, who tested HIV-positive stored from the 2004 and 2008 survey rounds, were tested for HCV antibodies (Advia/Centaur HCV, Siemens Healthcare Diagnostics Inc, Deerfield, IL) at the San Francisco General Clinical Laboratory. Results were merged with behavioral data which included history of injection drug use and history of being diagnosed for HCV by a doctor or nurse. Point prevalence estimates were adjusted for the survey design; the change in prevalence from 2004 to 2008 was assessed using the X2 test. We additionally examined mortality data from our local HIV/AIDS case registry to corroborate findings from our cross-sectional surveys.
